Navigation Links
Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data at ADA 2009
Date:6/8/2009

Analysis of Subjects with Moderately Severe Diabetic Neuropathy Shows Statistically Significant Improvement in Multiple Quantitative Neurological Endpoints

RICHMOND, Calif., June 8 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of as yet unreleased positive Phase 2 clinical data from its ZFP Therapeutic(TM) program to develop SB-509 as a treatment for diabetic neuropathy (DN) at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA), held in New Orleans, LA, from June 5 to 9, 2009. Data from Sangamo's SB-509-601 and SB-509-701A Phase 2 clinical trials demonstrated that SB-509 treatment resulted in statistically significant and clinically relevant improvements in subjects with moderate and severe DN as compared to placebo. SB-509 was well-tolerated in both multi-dose studies.

"We have learned a great deal from these data, which demonstrate positive activity of SB-509 in multiple clinically relevant measurements of nerve health," stated Dale Ando, M.D., Sangamo's Vice President of Therapeutic Development and Chief Medical Officer. "Data from our Phase 1 and both Phase 2 clinical trials have shown us that the dual angiogenic and neurotrophic effects of SB-509 are most effective in the later stages of DN when both diabetic microvascular disease and metabolic neuropathy are evident. The statistically significant improvement in SB-509-treated subjects across multiple independent clinical endpoints for DN has enabled definition of a responder group and is particularly encouraging for future trials in this patient population."

"SB-509 is the first drug candidate of its type designed to harness the body's own regenerative potential to address DN, a significant complication for diabetic patients," stated Alan Lewis, Ph.D., President and Chief
'/>"/>

SOURCE Sangamo
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Sangamo BioSciences Announces Presentation at the JMP Securities Research Conference
2. Sangamo BioSciences Reports First Quarter 2009 Financial Results
3. Sangamo BioSciences Provides Update on Companys Accomplishments in 2007 and 2008 Objectives
4. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
5. BD Biosciences Launches New Cell Analyzer for Complex Multicolor Experiments in Disease and Drug Development Research
6. ImQuest BioSciences and Arisyn Therapeutics Introduce Novel New HCV Therapeutic Agent at Hepatitis Conference
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2009 Financial Results
8. Stem Cell Biotherapy Sues Casey Nabavi, Co-Founder and Former President, for Conduct Resulting in Claims by SCB Patients Against Nabavi, Embezzling Money and Converting Other Assets Belonging to SCB and for Wrongfully Establishing Cellulogix Biosciences t
9. Epiphany Biosciences Initiates Program to Assess Valomaciclovir (EPB-348) as Adjunctive Therapy in Multiple Sclerosis (MS)
10. Pressure BioSciences, Inc. Provides Corporate Update
11. BIND Biosciences To Install First Siemens Simatic(R) PCS 7 Lab Process Control System in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... Rapids, MI (PRWEB) April 17, 2015 Enthusiasts ... CRUSH Grand Rapids, Saturday, April 25, 2015. The event will ... Reserve Wine & Food (201 Monroe Ave NW, Grand Rapids, ... from around the West Michigan area. Patrons are encouraged to ... of elegance and fun. , This year’s event will feature ...
(Date:4/17/2015)... York (PRWEB) April 17, 2015 ... allege this class of prescription medications increases the ... attack, stroke or other life-threatening cardiovascular event continue ... U.S. District Court, Northern District of Illinois. According ... U.S. Judicial Panel on Multidistrict Litigation (JPML) on ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 The American College of ... and Free Application Day on April 29. The event will be ... Square, located at 555 DeHaro St. in San Francisco, CA. , ... – Check in at the DeHaro campus (room F), 11:10 a.m. ... of campus, Noon – Light lunch with current students, faculty and ...
(Date:4/17/2015)... Carolina (PRWEB) April 17, 2015 With ... Dental Care has spent the last four years ... care, performing procedures ranging from general cleanings to dental ... a grand opening at their new office in North ... same services as their Concord office, including denture fittings, ...
(Date:4/17/2015)... April 17, 2015 Mario ... polish and perfect facial skin with its unique ... and blend of energizing botanicals. This cushiony gel-based ... that cause breakouts and inhibit penetration of special ... Ecuadorian Ivory Palm Seeds, This uncommon exfoliating ingredient ...
Breaking Medicine News(10 mins):Health News:Children’s Leukemia Foundation of Michigan Presents 3rd Annual CRUSH Grand Rapids 2Health News:Testosterone Treatment Lawsuits Increase, as New Report Indicates Over 200 Federal Cases Filed Since March 2Health News:Testosterone Treatment Lawsuits Increase, as New Report Indicates Over 200 Federal Cases Filed Since March 3Health News:Testosterone Treatment Lawsuits Increase, as New Report Indicates Over 200 Federal Cases Filed Since March 4Health News:American College of Traditional Chinese Medicine Hosts Open House 2Health News:Mario Badescu Skin Care Launches Botanical Exfoliating Scrub 2
... weight loss and preventive cardiology. The unique medical practice will offer ... pantry makeovers. , ... Denver, CO (PRWEB) August 10, ... change the way the medical community treats obesity by improving patients, ...
... Cryoablation attractive option for older patients with other medical ... News) -- A new method of freezing damaged cells ... is being used by gastroenterologists at the University of ... condition called Barrett,s esophagus can result from ongoing heartburn, ...
... selected iCRco, an American CR Company, as its new Digital Imaging ... diagnoses for our troops injured in battle. , ... ... an American CR Company, as its new Digital Imaging provider. iCRco,s ...
... Investor Conference Call on Monday, August 11, 2008 at 8:30am ... ... 8 Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ), a biopharmaceutical company focused ... treatment of life-threatening,diseases, including renal disease and cancer, today announced its results,for ...
... Inc., administrator for the,HealthShares(TM) Indexes, a series ... Traded Funds, today announced the following changes,effective ... August 11, 2008: Enzo Biochem,Inc. will replace ... the,HealthShares(TM) Infectious Disease Index and the HealthShares(TM),Composite ...
... MedQuist,Inc.,(Nasdaq: MEDQ ) the largest Medical Transcription Service ... the quarter ended June,30, 2008. Revenue for the second ... in the second quarter of 2007. The decrease in ... period was primarily due to,customer losses experienced during the ...
Cached Medicine News:Health News:Weight Loss and Disease Prevention Head Home 2Health News:New Therapy Freezes Out Esophageal Cancers 2Health News:US Military Chooses American Made iCRco Digital Radiography Systems 2Health News:Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results 2Health News:Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results 3Health News:Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results 4Health News:Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results 5Health News:Mergent, Inc. Announces Changes to the HealthShares(TM) Infectious Disease and HealthShares(TM) Composite Indexes 2Health News:MedQuist Reports Second Quarter 2008 Results 2Health News:MedQuist Reports Second Quarter 2008 Results 3Health News:MedQuist Reports Second Quarter 2008 Results 4Health News:MedQuist Reports Second Quarter 2008 Results 5Health News:MedQuist Reports Second Quarter 2008 Results 6Health News:MedQuist Reports Second Quarter 2008 Results 7Health News:MedQuist Reports Second Quarter 2008 Results 8Health News:MedQuist Reports Second Quarter 2008 Results 9
(Date:4/16/2015)... 16, 2015 Mallinckrodt plc (NYSE: ... announced that it has completed its acquisition of ... $2.3 billion. The Ikaria acquisition extends Mallinckrodt,s footprint ... into neonatal critical care with INOMAX ® ... a highly vulnerable patient population. It also accelerates ...
(Date:4/16/2015)... , April 16, 2015  Diplomat Pharmacy, Inc. ... Shannon Beltrand to their senior leadership team as ... be responsible for securing and properly monitoring Diplomat,s data, ... both internally and externally. Additionally, she will play key ... "We are very excited to have someone ...
(Date:4/16/2015)... YORK , April 16, 2015 An ... additional way to generate trimers from the major HIV ... could benefit future clinical development of HIV vaccine candidates ... the critical target on the surface of HIV for ... an important platform for AIDS vaccine discovery, says ...
Breaking Medicine Technology:Mallinckrodt Completes Acquisition Of Ikaria 2Mallinckrodt Completes Acquisition Of Ikaria 3Mallinckrodt Completes Acquisition Of Ikaria 4Mallinckrodt Completes Acquisition Of Ikaria 5Diplomat Names Shannon M. Beltrand as New CISO 2New Method Holds Promise for HIV Vaccine Development 2
Visionary OFFICE™ PM offers a Windows interface featuring medical billing, appointment scheduling and patient information....
... Medical Billing system allows a practice ... It is integrated with the EMR, ... system interfaces with electronic clearinghouses for ... a set of reports, it presents ...
... The Infinity Amylase CPNG3 single ... all the convenience of single liquid ... minimize operator error and provide quick ... of the Infinity Amylase CPNG3 reagent ...
... Infinity Uric Acid single liquid stable ... convenience of single liquid stability to ... error and provide quick result turnaround ... Infinity Uric Acid reagent provides a ...
Medicine Products: